BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 11179262)

  • 1. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Ajufo E; Ayers CR; Vigen R; Joshi PH; Rohatgi A; de Lemos JA; Khera A
    JAMA Cardiol; 2021 Feb; 6(2):179-187. PubMed ID: 33112372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin use for primary prevention in elderly patients.
    Terrosu P
    Monaldi Arch Chest Dis; 2016 Jun; 84(1-2):728. PubMed ID: 27374042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
    Kunutsor SK; Seidu S; Khunti K
    Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
    Helton TJ; Bavry AA; Kumbhani DJ; Duggal S; Roukoz H; Bhatt DL
    Am J Cardiovasc Drugs; 2007; 7(4):289-97. PubMed ID: 17696569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
    Hayden M; Pignone M; Phillips C; Mulrow C
    Ann Intern Med; 2002 Jan; 136(2):161-72. PubMed ID: 11790072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
    ; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
    Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ
    JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
    N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
    Antithrombotic Trialists' Collaboration
    BMJ; 2002 Jan; 324(7329):71-86. PubMed ID: 11786451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis.
    Selak V; Jackson R; Poppe K; Wu B; Harwood M; Grey C; Pylypchuk R; Mehta S; Choi YH; Kerr A; Wells S
    Ann Intern Med; 2019 Oct; 171(8):529-539. PubMed ID: 31525775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
    Cainzos-Achirica M; Miedema MD; McEvoy JW; Al Rifai M; Greenland P; Dardari Z; Budoff M; Blumenthal RS; Yeboah J; Duprez DA; Mortensen MB; Dzaye O; Hong J; Nasir K; Blaha MJ
    Circulation; 2020 May; 141(19):1541-1553. PubMed ID: 32233663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
    N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.